$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2017
[Report Updated: 31-03-2017]

Published by Global Markets Direct: 31 Mar 2017 | 51255 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever – Pipeline Review, H1 2017, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape.

Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Lassa Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lassa Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 9 and 4 respectively.

Lassa Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Lassa Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Lassa Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Lassa Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Lassa Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2017 [Report Updated: 31-03-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Lassa Fever (Lassa Hemorrhagic Fever) – Overview

    Lassa Fever (Lassa Hemorrhagic Fever) – Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Products under Development by Companies

    Lassa Fever (Lassa Hemorrhagic Fever) – Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Lassa Fever (Lassa Hemorrhagic Fever) – Companies Involved in Therapeutics Development

    Arno Therapeutics Inc

    Celgene Corp

    Etubics Corp

    Fab'entech SA

    Kineta Inc

    Profectus BioSciences Inc

    SIGA Technologies Inc

    Lassa Fever (Lassa Hemorrhagic Fever) – Drug Profiles

    AR-12 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CC-11050 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    FBH-003 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    KIN-1400 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    lassa fever vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    lassa fever vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    lassa fever vaccine – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    LHF-535 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ML-29 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibodies for Lassa Fever – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules for Lassa Fever – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ST-193 – Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Lassa Fever (Lassa Hemorrhagic Fever) – Dormant Projects

    Lassa Fever (Lassa Hemorrhagic Fever) – Product Development Milestones

    Featured News & Press Releases

    May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials

    Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals

    May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

51255 | GMDHC9122IDB

Number of Pages

43

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2018SummaryGlobal Markets Direct's lates...
26 Sep 2018 by Global Markets Direct USD $2,000 More Info
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2018
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2018SummaryGlobal Markets Direct's lates...
13 Mar 2018 by Global Markets Direct USD $2,000 More Info
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2016SummaryGlobal Markets Direct's lates...
21 Dec 2016 by Global Markets Direct USD $2,000 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H1 2017 [Report Updated: 31-03-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...